Annals of Surgical Oncology

, Volume 6, Issue 6, pp 546–552 | Cite as

Issues of Regret in Women With Contralateral Prophylactic Mastectomies

  • Leslie L. Montgomery
  • Katherine N. Tran
  • Melissa C. Heelan
  • Kimberly J. Van Zee
  • Mary Jane Massie
  • David K. Payne
  • Patrick I. Borgen
Original Article

Abstract

Background: Patients with a history of carcinoma of one breast have an estimated risk of 0.5% to 0.75% per year of developing a contralateral breast cancer. This risk prompts many women to consider contralateral prophylactic mastectomy (CPM) as a preventive measure. Virtually nothing is known about patient acceptance following CPM. We have developed a National Prophylactic Mastectomy Registry comprised of a volunteer population of 817 women from 43 states who have undergone prophylactic (unilateral or bilateral) mastectomy.

Methods: Of the 346 women with CPM who responded to national notices, 296 women returned detailed questionnaires. The information obtained included patient demographics, family history, reproductive history, ipsilateral breast cancer staging and treatment, as well as issues involving the CPM.

Results: At median follow-up of 4.9 years, the respondents were primarily married (79%), white (97%) women who had some level of college education or above (81%). These women cited the following reasons for choosing CPM: (1) physician advice regarding the high risk of developing contralateral breast cancer (30%); (2) fear of developing more breast cancer (14%); (3) desire for cosmetic symmetry (10%); (4) family history (7%); (5) fibrocystic breast disease (4%); (6) a combination of all of these reasons (32%); (7) other (2%); and (8) unknown (1%). Eighteen of the 296 women (6%) expressed regrets regarding their decision to undergo CPM. Unlike women with bilateral prophylactic mastectomies, regrets tended to be less common in the women with whom the discussion of CPM had been initiated by their physician (5%) than in the women who had initiated the discussion themselves (8%) (P = ns). Family history and stage of index lesion had no impact on regret status. The reasons for regret included: (1) poor cosmetic result, either of the CPM or of the reconstruction (39%); (2) diminished sense of sexuality (22%); (3) lack of education regarding alternative surveillance methods or CPM efficacy (22%); and (4) other reasons (17%).

Conclusions: To minimize the risk of regrets in women contemplating CPM, it is imperative that these women be counseled regarding an estimation of contralateral breast cancer risk, the alternatives to CPM, and the efficacy of CPM. In addition, these women should have realistic expectations of the cosmetic outcomes of surgery and understand the potential impact on their body image.

Key Words

Prophylactic mastectomy Contralateral breast cancer 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    Hartman LC, Schaid DJ, Woods JE, et al. 1999; Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340:77–84CrossRefPubMedGoogle Scholar
  2. 2.
    Hartmann L, Jenkins R, Schaid D, Yang P, et al. Prophylactic mastectomy: preliminary retrospective cohort analysis. Proc Am Assoc Cancer Res 1997;88:168.Google Scholar
  3. 3.
    Easton DF, Bishop DT, Ford D, Crockford GP, et al. Genetic linkage analysis in familial breast and ovarian cancer: results form 214 families. Am J Hum Genet 1993;52:678–701PubMedGoogle Scholar
  4. 4.
    Easton DF, Ford D, Bishop DT, 1995; The Breast Cancer Linkage Consortium, et al. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Am J Hum Genet 56:265–71PubMedGoogle Scholar
  5. 5.
    Ford D, Easton DF, Bishop DT, Narod SA, Goldar DE, 1994; the Breast Cancer Linkage Consortium, et al. Risks of cancer in BRCA1-mutation carriers. Lancet 343:692–5PubMedCrossRefGoogle Scholar
  6. 6.
    Schrag D, Kuntz KM, Garber JE, Weeks JC, et al. Decision analysiseffects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 1997;336:1465–71PubMedCrossRefGoogle Scholar
  7. 7.
    Grann VR, Panageas KS, Whang W, Antman KH, Neugut AI, et al. Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive and BRCA2-positive patients. J Clin Oncol 1998;16:979–85PubMedGoogle Scholar
  8. 8.
    Houn F, Helzsouer KJ, Friedman NB, Stefanek ME, et al. The practice of prophylactic mastectomy: A survey of Maryland surgeons. Am J Public Health 1995;85:801–5PubMedCrossRefGoogle Scholar
  9. 9.
    Fisher ER, Fisher B, Sass R, Wickerham L, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (protocol No 4). Cancer 1984;54:3002–11PubMedCrossRefGoogle Scholar
  10. 10.
    Rosen PP, Groshen S, Kinne DW, Hellman S, et al. Contralateral breast carcinoma: an assessment of risk and prognosis in stage I and stage II patients with 20-year follow-up. Surgery 1989; 106:904–10PubMedGoogle Scholar
  11. 11.
    Healey EA, Cook F, Schnitt SJ, Connolly JL, Harris JR, et al. Contralateral breast cancer: clinical characteristics and impact on prognosis. J Clin Oncol 1993;11:1545–52PubMedGoogle Scholar
  12. 12.
    Wanebo HJ, Senofsky GM, Fechner RE, Kaiser D, Lynn S, Paradies J, et al. Bilateral breast cancer: risk reduction by contralateral biopsy. Ann Surg 1985; 201:667–77PubMedCrossRefGoogle Scholar
  13. 13.
    Simkovich AH, Sclafani LM, Masri M, Kinne DW, et al. Role of contralateral breast biopsy in infiltrating lobular cancer. Surgery 1993; 114:555–7PubMedGoogle Scholar
  14. 14.
    Singletary SE, Taylor SH, Guinee VF, Whitworth PW, et al. Occurrence and prognosis of contralateral carcinoma of the breast. J Am Coll Surg 1994;178:390–6PubMedGoogle Scholar
  15. 15.
    Robinson E, Rennert G, Rennert HS, Neugut AI, et al. Survival of first and second primary breast cancer. Cancer 1993; 71:172–6PubMedCrossRefGoogle Scholar
  16. 16.
    Baker RR, Kuhajda FP, et al. The clinical management of a normal contralateral breast in patients with lobular breast cancer. Ann Surg 1989; 210:444–8PubMedCrossRefGoogle Scholar
  17. 17.
    Smith BL, Bertagnolli M, Klein BB, Batter S, Chang M, Douville LM, Eberlein TJ, et al. Evaluation of the contralateral breast: the role of biopsy at the time of treatment of primary breast cancer. Ann Surg 1992; 216:17–21PubMedCrossRefGoogle Scholar
  18. 18.
    Lee JSY, Grant CS, Donohue JH, Crotty TB, Harmsen WS, Ilstrup DM, et al. Arguments against routine contralateral mastectomy or undirected biopsy for invasive lobular breast cancer. Surgery 1995; 118: 640–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Mulvihill JJ, Safyer AW, Bening JK, et al. Prevention in familial breast cancer: counseling and prophylactic mastectomy. Prev Med 1982; 11:500–11PubMedCrossRefGoogle Scholar
  20. 20.
    Borgen PI, Hill AD, Tran KN, VanZee KJ, Massie MJ, Payne D, Biggs CG, et al. Patient regrets after bilateral prophylactic mastectomy. Ann Surg Oncol 1998; 5:603–6PubMedCrossRefGoogle Scholar
  21. 21.
    Cook LS, White E, Schwartz SM, McKnight B, Daling JR, Weiss NS, et al. A population-based study of contralateral breast cancer following a first primary breast cancer (Washington, United States). Cancer Causes Control 1996; 7:382–90PubMedCrossRefGoogle Scholar
  22. 22.
    Broet P, de la Rochefordiere A, Scholl SM, et al. 1995; Contralateral breast cancer: annual incidence and risk parameters. J Clin Oncol 13:1578–83PubMedGoogle Scholar
  23. 23.
    Lopez MJ, Porter KA, et al. The current role of prophylactic mastectomy. Surg Clin North Am 1996;76:231–42PubMedCrossRefGoogle Scholar
  24. 24.
    Ziegler LD, Kroll SS, et al. Primary breast cancer after prophylactic mastectomy. Am J Clin Oncol 1991;14:451–4PubMedGoogle Scholar
  25. 25.
    Gershenwald JE, Hunt KK, Kroll SS, et al. Synchronous elective contralateral mastectomy and immediate bilateral breast reconstruction in women with early-stage breast cancer. Ann Surg Oncol 1998;5:529–38PubMedCrossRefGoogle Scholar
  26. 26.
    Temple WJ, Lindsay RL, Magi E, Urbanski SJ, et al. Technical considerations for prophylactic mastectomy in patients at high risk for breast cancer. Am J Surg 1991;161:413–5PubMedCrossRefGoogle Scholar
  27. 27.
    Calson GW, Grossl N, Lewis MM, Temple JR, Styblo TM. Preservation of the inframammary fold: what are we leaving behind? Plast Reconstr Surg 1996;98:447–50CrossRefGoogle Scholar
  28. 28.
    Sterns EE, Fletcher WA, et al. Bilateral cancer of the breast: a review of clinical, histologic and immunologic characteristics. Surgery 1991;110:617–22PubMedGoogle Scholar
  29. 29.
    Harris RE, Lynch HT, Guirgis HA, et al. Familial breast cancer: risk to the contralateral breast. J Natl Cancer Inst 1978;60:955–60PubMedGoogle Scholar
  30. 30.
    Slattery ML, Kerber RA, et al. A comprehensive evaluation of family history and breast cancer risk. The Utah population database. JAMA 1993;270:1563–8CrossRefPubMedGoogle Scholar
  31. 31.
    Lesser ML, Rosen PP, Kinne DW, et al. Multicentricity and bilaterality in invasive breast carcinoma. Surgery 1982;91:234–40PubMedGoogle Scholar
  32. 32.
    Robson M, Gilewski T, Haas B, et al. 1998; BRCA-associated breast cancer in young women. J Clin Oncol 16:1642–9PubMedGoogle Scholar
  33. 33.
    Verhoog LC, Brekelmans CT, Seynaeve C, et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 1998;351:316–21PubMedCrossRefGoogle Scholar
  34. 34.
    Yeatmen TJ, Lyman GH, Smith SK, Reintgen DS, Cantor AB, Cox CE, et al. Bilaterality and recurrence rates for lobular breast cancer: considerations for treatment. Ann Surg Oncol 1997;4:198–202CrossRefGoogle Scholar
  35. 35.
    Chung MA, Cole B, Wanebo HJ, Bland KI, Chang HR, et al. Optimal surgical treatment of invasive lobular carcinoma of the breast. Ann Surg Oncol 1997;4:545–50PubMedCrossRefGoogle Scholar
  36. 36.
    Cody HS. Routine contralateral breast biopsy: helpful or irrelevant? Ann Surg 1997;225:370–6PubMedCrossRefGoogle Scholar
  37. 37.
    Habel LA, Moe RE, Daling JR, Holte S, Rossing MA, Weiss NS, et al. Risk of contralateral breast cancer among women with carcinoma in situ of the breast. Ann Surg 1997;225:69–75PubMedCrossRefGoogle Scholar
  38. 38.
    Hancock SL, Tucker MA, Hoppe RT, et al. Breast cancer after treatment of Hodgkin’s disease. J Natl Cancer Inst 1993;85:25–31PubMedCrossRefGoogle Scholar
  39. 39.
    Kroll SS, Miller MJ, Schusterman MA, Reece GP, Singletary SE, Ames F, et al. Rationale for elective contralateral mastectomy with immediate bilateral reconstruction. Ann Surg Oncol 1994;1:457–61PubMedCrossRefGoogle Scholar
  40. 40.
    de la Rochefordiere A, Mouret-Fourme E, Asselain B, Scholl SM, Campana F, Broet P, Fourquet A, et al. Metachronous contralateral breast cancer as first event of relapse. Int J Radiat Oncol Biol Phys 1996;36:615–21PubMedGoogle Scholar
  41. 41.
    Stefanek ME, Helzlsouer KJ, Wilcox PM, Houn F, et al. Predictors of and satisfaction with bilateral prophylactic mastectomy. Prev Med 1995;24:412–9PubMedCrossRefGoogle Scholar
  42. 42.
    Lerman C, Daly M, Sands C, et al. 1993; Mammography adherence and psychological distress among women at risk for breast cancer. J Natl Cancer Inst 85:1074–80PubMedCrossRefGoogle Scholar
  43. 43.
    Bostwick J. Preventive mastectomy. Ann Surg Oncol 1994;1:455–6PubMedCrossRefGoogle Scholar
  44. 44.
    Early Breast Cancer Trialists’ Collaborative Group, et al. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451–67CrossRefGoogle Scholar
  45. 45.
    Fisher B, Constantino J, Redmond C, et al. 1989;A randomized clinical trial evaluating tamoxifen in the treatment of patients with nodenegative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320:479–84PubMedCrossRefGoogle Scholar
  46. 46.
    Ragaz J, Coldman A, et al. Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes. J Clin Oncol 1998;16:2018–24PubMedGoogle Scholar
  47. 47.
    Garner B, et al. Prophylactic mastectomy: an unnecessary procedure. Ann Surg Oncol 1994;1:453–4CrossRefGoogle Scholar
  48. 48.
    Dean C, Chetty U, Forrest AP, et al. Effects of immediate breast reconstruction on psychosocial morbidity after mastectomy. Lancet 1983;1:459–62PubMedCrossRefGoogle Scholar
  49. 49.
    Gabriel SE, Woods JE, O’Fallon WM, Beard CM, Kurland LT, Melton LJ, et al. Complications leading to surgery after breast implantation. N Engl J Med 1997;336:677–82CrossRefPubMedGoogle Scholar

Copyright information

© The Society of Surgical Oncology, Inc. 1999

Authors and Affiliations

  • Leslie L. Montgomery
    • 1
    • 3
  • Katherine N. Tran
    • 1
  • Melissa C. Heelan
    • 1
  • Kimberly J. Van Zee
    • 1
  • Mary Jane Massie
    • 2
  • David K. Payne
    • 2
  • Patrick I. Borgen
    • 1
  1. 1.Department of SurgeryMemorial Sloan-Kettering Cancer CenterNew York
  2. 2.Department of PsychiatryMemorial Sloan-Kettering Cancer CenterNew York
  3. 3.Breast ServiceDept. of Surgery, Memorial Sloan-Kettering Cancer CenterNew York

Personalised recommendations